Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2018

View Archived Issues

Axsome reports topline phase I results on AXS-09

Valeant enters licensing agreement with Kaken for KP-470-based products for psoriasis

BioAtla treats first patient in phase I/II study of antibody-drug conjugate targeting AXL

DRP1 inhibitor mdivi-1 improves outcomes after experimental cardiac arrest

Novel microRNAs found largely overexpressed in children with severe sepsis

MabVax reports interim results from first cohort of phase I MVT-1075 study

Novavax reports topline results from phase I/II trial of NanoFlu in older adults

EMA grants orphan drug designation to MTD-119 for hepatocellular carcinoma

Synthetic Genomics' bacteriophage platform to be integrated with C3J's R&D programs

FDA approves ZTlido lidocaine topical system

Viela Bio spins out of MedImmune

Stimunity to receive investment from Portage Biotech

Endocyte launching phase III registration study of [177Lu]PSMA-617

Low NAA levels correlate with better outcomes in patients with severe TBI

MSD applies for approval of tazobactam sodium/ceftolozane sulfate combination in Japan

Asterias updates data from phase I/IIa SCiStar study of AST-OPC1 for severe spinal cord injury

Mylan and Revance sign global collaboration and license agreement for Botox biosimilar

Novel mTORC1/2 inhibitor DCZ-0358 overcomes bone marrow microenvironment to combat multiple myeloma

Sutro initiates phase I study of STRO-001 in advanced B-cell malignancies

Bristol-Myers Squibb presents phase Ib data for anti-PD-L1 BMS-936559 in sepsis

Stragen initiates phase I Paincart trial of STR-324

FronThera US Pharmaceuticals divulges new HIF2-alpha inhibitors

Novartis and Pear to collaborate on prescription software applications for schizophrenia and MS

Dompe Farmaceutici identifies novel FFAR1 agonists

Pharmascience discloses Tec family kinase inhibitors

Sunshine Lake Pharma presents influenza A H1N1 inhibitors

Jiangsu patents novel FGFR-4 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...